DUBLIN: Ovoca Bio, a biopharmaceutical company with a focus on women’s health, announced the appointment of Christopher Wiltshire as Chief Business Officer and Executive Director of the Board, effective immediately.
Mr. Wiltshire previously served as Non-Executive Director of the Board of Ovoca Bio.
Mr. Wiltshire is an experienced senior pharmaceutical and biotechnology executive with over 25 years of international experience.
He currently serves as the Chief Executive of Hematherix LLC which is developing a recombinant clotting factor, and is former head of Business Development and Licensing at La Jolla Pharmaceutical (NASDAQ). He has a successful consultancy practice which provides strategic advice to early and mid-stage biotechnology and pharmaceutical companies.
Mr. Wiltshire previously served in a number of senior positions at Pfizer, including as Head of Business Transactions and Investments within The Pfizer Incubator LLC. Mr. Wiltshire holds an MA in Engineering from the University of Cambridge and an MBA from the Darden Graduate School, University of Virginia.
As Chief Business Officer, Mr. Wiltshire will have a key role in delivering Ovoca Bio’s long-term vision of becoming a leader in the development and commercial partnering of novel medicines in areas of high unmet need that affect women, in particular through the ongoing clinical development of BP-101, Ovoca’s novel treatment for premenopausal women suffering from hypoactive sexual desire disorder (HSDD).
Kirill Golovanov, Chief Executive Officer of Ovoca Bio plc, said: “Christopher has significant global pharmaceutical industry experience and has contributed greatly to the strategic direction of Ovoca Bio as a Non-Executive Director. We are delighted to welcome him as fulltime CBO and Executive Director. His appointment comes at an exciting time for the business as we seek to ramp up clinical development activities for our lead asset, BP-101, in major global markets.”
Christopher Wiltshire said: “Women’s health remains an under-served area with significant unmet medical needs. BP-101 has great potential as a treatment for women suffering from HSDD and I look forward to working more closely with the team at Ovoca Bio to drive its development and ultimate commercialisation internationally.”
Ovoca Bio is a European-based biopharmaceutical company with a focus on women’s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.
The Company’s lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.
Ovoca Bio is seeking to develop the drug for major global markets – in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.
Leave a Reply